Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
| References: | Int J Oncol. 1996 Dec;9(6):1099-105. (PMID: 21541617) Apoptosis. 2002 Aug;7(4):367-72. (PMID: 12101396) EMBO J. 2001 Apr 2;20(7):1630-9. (PMID: 11285227) Recent Prog Horm Res. 1993;48:365-91. (PMID: 8382830) Nucleic Acids Res. 1994 Oct 11;22(20):4354-5. (PMID: 7937169) Cancer. 1998 Oct 1;83(7):1335-43. (PMID: 9762934) Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8318-23. (PMID: 8710868) Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):692-7. (PMID: 9892695) Biochim Biophys Acta. 1998 Aug 19;1378(1):F21-59. (PMID: 9739759) Front Neuroendocrinol. 2001 Oct;22(4):248-91. (PMID: 11587553) Int J Oncol. 1995 Oct;7(4):749-54. (PMID: 21552898) Oncogene. 2000 Aug 3;19(33):3717-26. (PMID: 10949925) Cancer Res. 1997 Oct 1;57(19):4285-300. (PMID: 9331090) Prostate. 2000 Jul 1;44(2):172-80. (PMID: 10881027) Br J Cancer. 1999 Nov;81(6):966-71. (PMID: 10576652) Endocr Rev. 2000 Jun;21(3):215-44. (PMID: 10857553) Am J Physiol Cell Physiol. 2001 Jan;280(1):C34-45. (PMID: 11121374) Lung Cancer. 2001 Dec;34 Suppl 2:S7-15. (PMID: 11720736) Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14894-8. (PMID: 10611309) Cancer. 2001 Jul 15;92(2):386-94. (PMID: 11466694) Hum Mutat. 2002 Jun;19(6):607-14. (PMID: 12007217) Oncogene. 2003 Feb 13;22(6):853-7. (PMID: 12584565) Trends Endocrinol Metab. 1999 Dec;10(10):383-391. (PMID: 10542394) Nature. 1985 Aug 29-Sep 4;316(6031):823-6. (PMID: 2993906) Cell. 1992 Aug 21;70(4):523-6. (PMID: 1505019) Adv Cancer Res. 1996;68:183-223. (PMID: 8712068) Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10561-6. (PMID: 10962031) Life Sci. 1983 Nov 7;33(19):1939-44. (PMID: 6139724) Cancer Lett. 2000 Dec 20;161(2):149-55. (PMID: 11090963) Cancer Res. 1994 Sep 15;54(18):4855-78. (PMID: 8069852) Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3804-8. (PMID: 8170991) Science. 1994 Jul 15;265(5170):346-55. (PMID: 8023157) Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):358-66. (PMID: 9279210) J Natl Cancer Inst. 2003 Jul 2;95(13):961-70. (PMID: 12837832) Science. 1991 Jul 5;253(5015):49-53. (PMID: 1905840) Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11866-71. (PMID: 12186980) Nucleic Acids Res. 1996 Jan 1;24(1):141-6. (PMID: 8594564) Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10555-60. (PMID: 10962030) |
|---|---|
| Molecular Sequence: | GENBANK AY429684 |
| Substance Nomenclature: | 0 (DNA Primers) 0 (DNA, Complementary) 0 (Peptide Fragments) 0 (RNA, Neoplasm) 0 (bombesin(6-14), Hca(6)-Leu(13)-psi(CH2N)-Tac(14)-) 67763-96-6 (Insulin-Like Growth Factor I) 9034-39-3 (Growth Hormone-Releasing Hormone) PX9AZU7QPK (Bombesin) |
| Entry Date(s): | Date Created: 20031209 Date Completed: 20040420 Latest Revision: 20240322 |
| Update Code: | 20240322 |
| PubMed Central ID: | PMC307654 |
| DOI: | 10.1073/pnas.2536558100 |
| PMID: | 14660794 |
| Autor: | Kanashiro CA; Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112-2699, USA., Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL |
| Jazyk: | angličtina |
| Zdroj: | Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2003 Dec 23; Vol. 100 (26), pp. 15836-41. Date of Electronic Publication: 2003 Dec 05. |
| DOI: | 10.1073/pnas.2536558100 |
| Abstrakt: | We investigated the effects of growth hormone-releasing hormone (GHRH) antagonists, JV-1-65 and JV-1-63, and bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC-3940-II on DMS-153 human small cell lung carcinoma xenografted into nude mice. Treatment with 10 microg/day JV-1-65 or RC-3940-II decreased tumor volume by 28% (P < 0.05) and 77% (P < 0.01), respectively, after 42 days compared with controls. Combination of JV-1-65 and RC-3940-II induced the greatest inhibition of tumor proliferation (95%; P < 0.01), suggesting a synergism. Western blotting showed that the antitumor effects of these antagonists were associated with inhibition of the expression of the mutant tumor suppressor protein p53 (Tp53). Mutation was detected by sequence analysis of the p53 gene at codon 155: ACC [Thr] --> CCC [Pro]. Combination of JV-1-65 and RC-3940-II decreased the levels of mutant p53 protein by 42% (P < 0.01) compared with controls. JV-1-65, JV-1-63, and RC-3940-II, given singly, reduced mutant p53 protein expression by 18-24% (P < 0.05). Serum insulin-like growth factor (IGF)-I levels were diminished in animals receiving GHRH antagonists. mRNA levels for IGF-II, IGF receptor-I, GRP receptor, and EGF receptor in tumors were significantly decreased by combined treatment with JV-1-65 and RC-3940-II. DMS-153 tumors expressed mRNAs for GHRH and GHRH receptor splice variants 1 and 2, suggesting that GHRH could be an autocrine growth factor. Proliferation of DMS-153 cells in vitro was stimulated by GRP and IGF-II and inhibited by JV-1-65. This study indicates that GHRH antagonists and BN/GRP antagonist inhibit the growth of DMS-153 small cell lung carcinoma concomitantly with the expression of mutant Tp53, which might uncouple the signal transduction pathways for cell growth stimulation. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|